Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Extracellular vesicle mimics made from iPS cell-derived mesenchymal stem cells improve the treatment of metastatic prostate cancer

Fig. 2

Biodistribution of systemically infused DiR-NVs in mice carrying subcutaneous prostate cancer. Nude mice carrying subcutaneous Luc2-PC3 tumors were randomly grouped and IP infused with PEGylated liposomes or NVs labeled with DiR. a, b The representative in vivo imaging of Luc2 and DiR signals at 24 h after infusion from both the dorsal and ventral sides. c The relative intensities of in vivo DiR signals in Luc2+ tumor region and non-tumor regions were quantified at 3, 12, 24, and 48 h after infusion as percentages of total DiR signals. df Tumors (T) and organs were collected 24 h after infusion for ex vivo imaging and consequent quantification. H, heart; Ln, lungs; Lv, liver; S, spleen; K, kidneys; GI, gastrointestinal tract; P, pancreas. N = 4 in all assays, *p < 0.05

Back to article page